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Objective. To study the activation of coagulation and fibrinolysis before, during and after surgical revascularisation in
patients with critical limb ischemia (CLI).
Design. Prospective clinical study.
Materials and methods. Forty patients with CLI underwent femoro-popliteal or femoro-distal reconstruction and were
compared to a control-group. Measurements of prothrombin-fragment 1 þ 2 (F1 þ 2) and thrombin–antithrombin complex
(TAT) assessed activation of coagulation. Fibrinolysis was determined by tissue plasminogen activator (tPA), plasminogen
activator inhibitor (PAI-1) and fibrin degradation product (D-dimer). The inflammatory mediators: Interleukin 2 receptor
(IL-2-rec), Interleukin 6 (IL-6), Interleukin 10 (IL-10) and Monocyte chemoattractant protein 1 (MCP-1) was also analysed.
Results. Patients (in 35 of the 40 reconstruction was possible) were operated upon using either vein (n ¼ 23) or ePTFE
(n ¼ 12) grafts. Patients with CLI had a preoperative prothrombotic state as indicated by high TAT-levels and also ongoing
fibrinolysis with high levels of t-PA and D-dimer. After reperfusion an ongoing prothrombotic state for the first week was
demonstrated. A significant as well as defective fibrinolysis was also seen with increased levels of tPA and D-dimer
unopposed by PAI-1 after one week and also after 30 days. Increased levels of inflammatory mediators IL-6, IL-10 and MCP-
1 was observed after reperfusion and normalised after 30 days.
Conclusion. This study demonstrates significant disturbances of both the coagulation and fibrinolytic systems before,
during and after revascularisation for CLI. This was accompanied by release of inflammatory mediators. A prothrombotic
state and increased fibrinolysis were evident also 30 days after successful revascularisation.
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Introduction
Atherosclerotic arterial disease is usually associated
with changes in activation of blood coagulation and
fibrinolysis resulting in a prothrombotic state. This is
probably due to continuous thrombus formation on
arterial vessel wall defects and reactive fibrinolysis.1
Patients with peripheral arterial occlusive disease
(PAOD) seems to have more widespread defects as
compared with isolated coronary artery disease
(CAD).1 – 4 This provides a large source for activation
of coagulation and subsequent triggering of fibrino-
lysis. In patients with chronic critical limb ischemia
(CLI), ulcers and gangrene creates an inflammatory
response, which may add to the hypercoagulability.
The mechanism includes release of cytokines such as
tumour necrosis factor (TNF-a) interleukin-1 (IL-1),
inducing procoagulant activity on endothelial cells.5
Proinflammatory cytokines also stimulate production
of PAI-1, resulting in a fibrinolytic shutdown, which
add to the hypercoagulable state.6,7
Infrainguinal reconstructions are mostly performed
on severely ischemic limbs as salvage procedures.
Unfortunately a proportion of these grafts occludes
within 30 days with resulting detoriation of the
ischemia and risk of limb loss. The reasons for early
graft occlusions have been attributed to technical
problems and poor outflow. Increased coagulation
and fibrinolytic shutdown as important mechanisms
for both early and late graft occlusions has also been
demonstrated.7 Antithrombotic treatment is important
to prevent from graft occlusion but also other ischemic
events.8 – 10 Patients with CLI frequently do have
severe generalised atherosclerosis and increased levels
of thrombotic mediators. A surgical procedure
might induce a procoagulant response, which further
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promotes a pro-thrombotic state and possibly an
adverse outcome for the procedure. The relationship
as well as time-course for activation of coagulation and
fibrinolysis as well as inflammatory response has not
been well investigated in this group of high-risk
patients.
This study was performed to investigate if patients
with CLI have an increased pro-thrombotic state as
compared to a control group. The influence of the
vascular reconstruction on activation of coagulation
and fibrinolysis as well as the inflammatory response
was also examined during and after revascularisation
up to 30 days postoperatively.
Material and Methods
Approval for this study was obtained from the
research ethics committee; faculty of Medicine, Uni-
versity of Uppsala and informed consent was obtained
from all subjects before their participation.
The study group consisted of forty consecutive
patients with CLI, (European consensus for critical
limb ischemia)11 who had infrainguinal bypass graft-
ing. The baseline characteristics are presented in Table
1. The indication for surgery was pain at rest in 11
patients (28%) and ulceration/gangrene in 29 patients
(72%). All procedures were performed in epidural
anaesthesia using intermittent bolus doses through an
indwelling catheter. Patients were maintained on
either 75 mg ASA or 75 mg clopidogrel daily until 30
days postoperatively. Forty milligram of enoxaparin
was given 12 h preoperatively daily until discharge.
Five thousand units of unfractionated heparin were
used intraoperatively before clamping.
In five patients, the planned recipient artery was
considered not suitable for a bypass procedure and the
patients were excluded from intra and postoperative
blood sampling. The distal anastomosis was to the
popliteal artery in 17 patients (48%) and to tibial
vessels in 18 (52%). In situ vein grafts were used in 23
patients. Twelve patients had ePTFE (Goretexw, Gore
and Ass, Flagstaff, USA) grafts with a distal vein cuff.
Twenty healthy persons, 16 men and four women,
with a median age of 72 years (range 66–79) without
clinical signs or history of cardiovascular, malignant or
chronic inflammatory diseases served as control
group. None of the controls were on any anticoagulant
medication.
Baseline blood-samples were obtained preopera-
tively and before administration of low-molecular
weight heparin from the cubital vein in both patients
and control group. Two volumes, each containing
4.5 ml of blood were sampled in tubes containing
0.5 ml of 0.129 M citrate (Becton Dickinson Vacutainer
Systems Eur. B.P. 3738241 Myelan Cedex, France).
Intra and postoperative samples were obtained before
clamping, 30 and 60 min after reperfusion, 24 h, 7 and
30 days postoperatively. Blood was also sampled from
the ipsilateral femoral vein intraoperatively. Within
30 min after blood sampling, plasma was separated by
centrifugation at 2500 rpm for 15 min, frozen in
270 8C and stored. Quantitative determination of
fibrinogen levels in plasma was performed by the
clotting method of Clauss (FibriPrestw Automat 2,
Triolab AB, Diagnostica Stago, France). Using ELISA-
kit (Behringwerke AG, Germany) levels of prothrom-
bin-fragment 1 þ 2 (F1 þ 2), thrombin–antithrombin
complex (TAT) were measured. Enzyme immunoassay
for quantitative determination of tissue plasminogen
activator antigen (tPA) was performed (Imulysew tPA,
Biopool, Umea˚, Sweden). Determination of active
plasminogen activator inhibitor type 1 (PAI-1) was
performed by using a bioimmunoassay (Biopool
Chromolizew, Biopool, Umea˚, Sweden). Crosslinked
fibrin degradation product (D-dimer) was analysed by
using a sandwich enzyme immunoassay (Enzygnostw
D-dimer micro, Behring diagnostics GmbH, Marburg,
Germany). Quantitative sandwich enzyme immunoas-
say technique (Quantikinew, R&D Systems, Inc, USA)
were used for levels of cytokines; Interleukin 2 soluble
receptor (IL-2-rec), Interleukin-6 (IL-6), Interleukin 10
(IL-10) and Monocyte chemoattractant protein 1
(MCP-1). All assays were performed in duplicate and
interassay variability was ,5%.
Statistics
Data were analysed using SPSS for windows release
10.0. Differences between groups were analysed with
Mann–Whitney U test. Differences between repeated
measurements within groups were analysed with
Wilcoxon signed rank test. Results are presented as
two-tailed level of probability, p , 0:05 was con-
sidered significant. Data are presented as the median
and 25th–75th percentiles.
Table 1. Patient data.
Control CLI
Sex (M/F) 16/4 23/17
Age 72 (66–79) 74 (58–89)
Smoker 0 24 (60%)
MI 0 9 (22%)
Diabetes 0 13 (32%)
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Results
All patients had an intraoperative completion angio-
gram and a satisfactory technical result was demon-
strated in each patient. The primary patency for the
grafts at 30 days was 91% (32/35) and secondary
patency was 94% (33/35). One patient with an
occluded graft required a below knee amputation.
Two patients had an acute myocardial infarction in the
immediate postoperative period; otherwise no other
major thrombotic events were demonstrated during
the 30-day follow-up.
Preoperative characteristics of coagulation and fibrinolysis
As demonstrated in Fig. 1, median preoperative values
of fibrinogen and TAT were significantly elevated in
patients with CLI as compared to controls. No
difference between controls and patients with CLI
was found in F 1 þ 2. A significant preoperative
elevation of tPA and D-dimer in patients with CLI
compared to controls was found (Fig. 2).
Intra and postoperative changes in coagulation and
fibrinolysis
Intraoperatively both TAT and F 1 þ 2 increased after
reperfusion whereas the levels of fibrinogen
decreased. During the postoperative period (7, 30
days), fibrinogen was significantly elevated compared
to preoperative levels (Fig. 1).
During the immediate reperfusion period a signifi-
cant increase of PAI-1 was found, this was followed by
return to normal within 7 days. An initial decrease of
tPA in the immediate reperfusion period was followed
by increased levels not returning to preoperative levels
at 30 days. A significant elevation of D-dimer
remained 7 and 30 days postoperatively (Fig. 2).
Preoperative characteristics of inflammatory markers
Preoperatively, IL-6 and sIL-2R in patients with CLI
were significantly elevated compared to controls.
MCP-1 and IL-10 were within the normal reference
interval in both controls and patients with CLI (Fig. 3).
Fig. 1. Fibrinogen, F 1 þ 2 and TAT before surgery (preop), before clamp, 30, 60 min, 24 h after reperfusion and 7, 30 days
postoperatively. Values are median and 25th–75th percentile range. #Higher than controls p , 0:05; ##p , 0:01; ###p , 0:001.
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Intra- and postoperative changes of inflammatory markers
After 30 min of reperfusion a significant increase in
levels IL-6, Il-10 and MCP-1 was found. IL-6 and IL-10
remained elevated until 24 h postoperatively. Levels of
IL-6 and IL-10 returned to normal on postoperative
day 7 and did not change thereafter. A significant
increase of sIL-2R was observed 7 days postopera-
tively and did not return to normal at 30 days (Fig. 3).
Discussion
This study demonstrates evidence that both blood
coagulation and fibrinolysis are activated in patients
with CLI compared to an age-matched control group.
Significantly increased levels of inflammatory markers
IL-6, MCP-1 and IL-10 accompanied this. These
findings are consistent with previous studies in
patients with PAOD where biochemical evidence of a
prothrombotic state as well as increased fibrinolysis
has been demonstrated.1 – 4,12 This is in contrast to
patients with stable coronary artery disease (CAD)
alone where no such activation was found.1 A
correlation between the extent of PAOD and hemo-
static dysbalance as well as impaired fibrinolytic
avtivity has been demonstrated.1 – 4 Fibrinogen has
been identified as a major risk marker for arterial
disease and a correlation between the angiographic
severity of PAOD and levels of fibrinogen and fibrin
degradation products (FDP) has been demonstrated.13,
14 Similar results were found in the present study
where significantly increased preoperative levels of
fibrinogen in patients with CLI were found. Patients
included in this study all had extensive PAOD with
ongoing CLI and angiographic evidence of extensive
arterial occlusive disease. The patients with CLI had
signs of active thrombin generation as demonstrated
by elevated levels of TAT. Increased turnover of fibrin
were also found as indicated by high preoperative
levels of both tPA and D-dimer and probably reflects
biochemical evidence for ongoing subclinical throm-
bus formation. A similar response was recently
demonstrated by Li et al.15 after coronary artery
bypass surgery with a marked pro-thrombotic and
inflammatory response persisting during the first
week after surgery. Previous studies have also found
evidence of high levels of circulating PAI-1in patients
Fig. 2. tPA, PAI-1 and D-Dimer before surgery (preop), before clamp, 30, 60 min, 24 h after reperfusion and 7, 30 days
postoperatively. Values are median and 25th to 75th percentile range. ##Higher than controls p , 0:01; ###p , 0:001; *Higher
than preoperative values, p , 0:05; **p , 0:01; ***p , 0:001:
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with PAOD reflecting a poor fibrinolytic capacity but
were not found in this study.7,16 Consumption of active
PAI-1 due to excessive fibrin formation and sub-
sequent binding might explain such a finding.
Patients with CLI also had elevated levels of IL-6
and sIL-2R preoperatively, indicating an ongoing
inflammatory reaction. This might be due to the
presence of ongoing tissue-destruction in severely
ischemic limbs. Unfortunately the patient group was
to small to analyse for differences between rest-pain
and more severe ischemia with tissue-loss. Several
interactions between inflammatory mediators such as
cytokines and coagulation system has been described,
one possible mechanism is induction of synthesis and
secretion of fibrinogen from the hepatocytes by IL-6 as
well as TNF-a and IL-1.5,17,18 These cytokines are also
important inducers of structural changes in vascular
endothelium, which becomes thrombogenic. A recent
clinical study demonstrated an association between
IL-6 2174G . C polymorphism and risk of coronary
heart disease and also elevated levels of fibrinogen and
C-reactive protein.19
Significant elevations of both F 1 þ 2 and TAT but a
significant decrease of fibrinogen were noted in
samples taken after reperfusion. This indicates an
acute generation of thrombin and also consumption of
fibrinogen. F 1 þ 2 was elevated even 7 days after
completed reconstruction and possibly reflects
remaining active F 1 þ 2 on the thrombus. The same
response has also been found after successful revas-
cularisation in acute limb ischemia20 and also after
acute myocardial infarction.21 Activation of coagu-
lation was initially accompanied by decreased levels of
tPA and increased activity of its primary inhibitor PAI-
1 during the first 24 h. This has been documented after
vascular reconstructions22 but also other surgical
procedures23 and indicates a fibrinolytic shutdown.
Initial signs of shutdown were subsequently followed
by marked generation of D-dimer and elevated levels
of tPA suggesting active fibrinolysis. A possible source
might be the vascular graft itself or revascularized
previous ischemic tissue with increased turnover of
fibrin. No significant differences, however, were seen
between sampling in femoral vein versus cubital vein.
A strong inflammatory reaction in the initial post-
operative period was seen with high levels of IL-6.
Elevated levels of MCP-1 and IL-10 were noted during
the procedure and until 24 h after reperfusion. In
Fig. 3. IL-6, IL-10, MCP-1 and sIL-2R before surgery (preop), before clamp, 30, 60 min, 24 h after reperfusion and 7, 30 days
postoperatively. Values are median and 25th to 75th percentile range. #Higher than controls p , 0:05; ##p , 0:01 *Higher than
preoperative values, p , 0:05; **p , 0:01; ***p , 0:001:
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general, cytokines are thrombogenic and TNF-a, IL-1
as well as Il-6 contributes to thrombin formation in
sepsis.24 MCP-1 also stimulate coagulation, the mech-
anism is by stimulation of TF (tissue factor) expression
on monocytes.25,26 IL-10 is an anti-inflammatory
cytokine and affects the coagulation pathway mainly
by inhibiting the production of TF.27 Thus, IL-10 may
have a role in inhibiting a procoagulant response.
Blood was sampled both from a peripheral vein and
from the femoral vein, supposed to directly reflect
local changes. No major differences, however, were
noted, which probably reflects a rapid steady state
between peripheral and central venous blood. With
the present findings the hypothesis about major
production of measured parameters, being produced
in the ischemic leg before and after reperfusion leg
cannot be proven.
Current clinical practice today includes antithrom-
botic treatment to prevent graft occlusion but differs
between countries. Platelet-aggregating inhibitors
seems to be the most commonly used followed by
oral anticoagulants. The Dutch bypass study (BOA)
demonstrated a benefit for oral anticoagulation (war-
farin) in preventing infra-inguinal-vein-graft occlu-
sion compared to aspirin, but was associated with
more bleeding episodes.8 – 10 With signs of a prothrom-
botic state and increased fibrinolysis even 30 days after
successful revascularisation as in the present study,
adjunctive long-term antithrombotic treatment seems
to be justified to prevent further ischemic events.
Other oral anticoagulants are currently being devel-
oped and might provide less risk of haemorrhage and
easier to monitor compared to warfarin.28
In summary, we observed that patients with CLI
have significant disturbances of both the coagulation
and fibrinolytic systems before, during and after
revascularisation for CLI. This was accompanied by
release of inflammatory mediators. A prothrombotic
state and increased fibrinolysis was present 7 and also
30 days after successful revascularisation.
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